Insulet Statistics
Total Valuation
Insulet has a market cap or net worth of $21.62 billion. The enterprise value is $21.90 billion.
Market Cap | 21.62B |
Enterprise Value | 21.90B |
Important Dates
The last earnings date was Thursday, August 7, 2025, before market open.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Insulet has 70.39 million shares outstanding. The number of shares has decreased by -4.15% in one year.
Current Share Class | 70.39M |
Shares Outstanding | 70.39M |
Shares Change (YoY) | -4.15% |
Shares Change (QoQ) | -4.67% |
Owned by Insiders (%) | 0.31% |
Owned by Institutions (%) | 102.65% |
Float | 70.08M |
Valuation Ratios
The trailing PE ratio is 92.42 and the forward PE ratio is 61.09. Insulet's PEG ratio is 2.35.
PE Ratio | 92.42 |
Forward PE | 61.09 |
PS Ratio | 9.14 |
Forward PS | 7.84 |
PB Ratio | 14.78 |
P/TBV Ratio | 16.52 |
P/FCF Ratio | 53.38 |
P/OCF Ratio | 41.88 |
PEG Ratio | 2.35 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 46.02, with an EV/FCF ratio of 54.06.
EV / Earnings | 92.74 |
EV / Sales | 9.28 |
EV / EBITDA | 46.02 |
EV / EBIT | 55.59 |
EV / FCF | 54.06 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.96.
Current Ratio | 2.26 |
Quick Ratio | 1.55 |
Debt / Equity | 0.96 |
Debt / EBITDA | 2.94 |
Debt / FCF | 3.46 |
Interest Coverage | 7.91 |
Financial Efficiency
Return on equity (ROE) is 19.18% and return on invested capital (ROIC) is 9.30%.
Return on Equity (ROE) | 19.18% |
Return on Assets (ROA) | 7.75% |
Return on Invested Capital (ROIC) | 9.30% |
Return on Capital Employed (ROCE) | 16.02% |
Revenue Per Employee | $605,000 |
Profits Per Employee | $60,538 |
Employee Count | 3,900 |
Asset Turnover | 0.74 |
Inventory Turnover | 1.60 |
Taxes
In the past 12 months, Insulet has paid $34.60 million in taxes.
Income Tax | 34.60M |
Effective Tax Rate | 12.78% |
Stock Price Statistics
The stock price has increased by +61.30% in the last 52 weeks. The beta is 1.35, so Insulet's price volatility has been higher than the market average.
Beta (5Y) | 1.35 |
52-Week Price Change | +61.30% |
50-Day Moving Average | 300.04 |
200-Day Moving Average | 275.88 |
Relative Strength Index (RSI) | 60.52 |
Average Volume (20 Days) | 648,631 |
Short Selling Information
The latest short interest is 2.12 million, so 3.02% of the outstanding shares have been sold short.
Short Interest | 2.12M |
Short Previous Month | 2.21M |
Short % of Shares Out | 3.02% |
Short % of Float | 3.03% |
Short Ratio (days to cover) | 2.79 |
Income Statement
In the last 12 months, Insulet had revenue of $2.36 billion and earned $236.10 million in profits. Earnings per share was $3.32.
Revenue | 2.36B |
Gross Profit | 1.66B |
Operating Income | 393.90M |
Pretax Income | 267.50M |
Net Income | 236.10M |
EBITDA | 475.80M |
EBIT | 393.90M |
Earnings Per Share (EPS) | $3.32 |
Balance Sheet
The company has $1.12 billion in cash and $1.40 billion in debt, giving a net cash position of -$278.10 million or -$3.95 per share.
Cash & Cash Equivalents | 1.12B |
Total Debt | 1.40B |
Net Cash | -278.10M |
Net Cash Per Share | -$3.95 |
Equity (Book Value) | 1.46B |
Book Value Per Share | 20.78 |
Working Capital | 1.27B |
Cash Flow
In the last 12 months, operating cash flow was $516.20 million and capital expenditures -$111.20 million, giving a free cash flow of $405.00 million.
Operating Cash Flow | 516.20M |
Capital Expenditures | -111.20M |
Free Cash Flow | 405.00M |
FCF Per Share | $5.75 |
Margins
Gross margin is 70.18%, with operating and profit margins of 16.69% and 10.01%.
Gross Margin | 70.18% |
Operating Margin | 16.69% |
Pretax Margin | 11.47% |
Profit Margin | 10.01% |
EBITDA Margin | 20.17% |
EBIT Margin | 16.69% |
FCF Margin | 17.16% |
Dividends & Yields
Insulet does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 4.15% |
Shareholder Yield | 4.15% |
Earnings Yield | 1.09% |
FCF Yield | 1.87% |
Analyst Forecast
The average price target for Insulet is $324.68, which is 5.73% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $324.68 |
Price Target Difference | 5.73% |
Analyst Consensus | Strong Buy |
Analyst Count | 19 |
Revenue Growth Forecast (5Y) | 16.34% |
EPS Growth Forecast (5Y) | 8.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Insulet has an Altman Z-Score of 6.86 and a Piotroski F-Score of 7.
Altman Z-Score | 6.86 |
Piotroski F-Score | 7 |